iqvia semaglutide tirzepatide prescriptions us q3 2024 Obesity Deep Dive: The Unparalleled Launch Success of Mounjaro and Zepbound Eli Lilly Stock Will 'Dominate'

Discussion The results of the current meta-analysis, that included 60,080 patients with T2DM, 14,804 of whom without established CV disease, demonstrate that GLP-1RA reduce the risk of MACE by 14% in the overall diabetic population, with an apparently greater effect in patients with known CV disease as compared with those without established CV disease (16% vs 6% reduction, respectively)

Most state Medicaid programs will cover it for diabetes, but that coverage might require prior authorization

It is essential to check with your insurance provider about coverage for GLP-1 medications for weight loss, as coverage can vary significantly, and prior authorization may be required

So why arent both semaglutide and tirzapetide produced recombinantly